Future directions of neoadjuvant therapy in pancreatic cancer.
Oncoscience
; 7(7-8): 44-46, 2020 Jul.
Article
en En
| MEDLINE
| ID: mdl-32923514
ABSTRACT
Neoadjuvant therapy with conventional chemotherapies have visibly improved the prognosis of locally advanced pancreatic cancer (PCa). However, molecular targeted therapies that have provided durable responses in other tumor entities, have not yet found access into neoadjuvant therapy of PCa. In fact, due to the presence of the tumor burden serving as an antigen source for T cell priming, neoadjuvant chemotherapy may unleash a more potent antitumoral immune response than adjuvant or palliative chemotherapy.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Oncoscience
Año:
2020
Tipo del documento:
Article
País de afiliación:
Alemania